AKBA - アケビア・セラピュ―ティクス (Akebia Therapeutics Inc.) アケビア・セラピュ―ティクス

 AKBAのチャート


 AKBAの企業情報

symbol AKBA
会社名 Akebia Therapeutics Inc (アケビア・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アケビ・セェラァピュゥーティィクス(Akebia Therapeutics Inc.)はバイオ医薬品企業である。同社は低酸素誘導性因子(HIF)の生物学に基づいた治療薬の開発と商品化に従事する。同社の主力な候補製品のバダデュスタットは、慢性腎疾患(CKD)における貧血の治療に適応される。同社は経口療法におけるバダダスタットの開発を行う。バダスタットは、CKDの貧血の治療のためのフェーズⅢ開発におけるHIF-プロリルヒドロキシラーゼ(HIF-PH)阻害剤である。また、同社は疾患を標的とするHIFベースの候補製品のポートフォリオの開発に従事する。同社のポートフォリオは、社内で開発された候補製品のAKB-6899、ライセンス取得済みの候補製品のAKB-5169を含む。AKB-5169は、炎症性腸疾患(IBD)のための経口治療として開発中の前臨床化合物である。   アケビア・セラピュ―ティクスは米国のバイオ医薬品会社。低酸素誘導因子、HIF、生物学と腎臓病の患者用製品の商品化に基づく独自の治療法の開発に焦点を当てる。 「HIF」は体内で赤血球の生産と貧血を治療する。「AKB-6548」は一日一回の経口療法、「AKB-6548」は安定的にヘモグロビンレベルを上昇させる。本社はマサチュ―セッツ州ケンブリッジ。   Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
本社所在地 245 First Street Suite 1100 Cambridge MA 02142 USA
代表者氏名 Muneer A. Satter ムネア・サッター
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-871-2098
設立年月日 39114
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 114人
url www.akebia.com
nasdaq_url https://www.nasdaq.com/symbol/akba
adr_tso
EBITDA EBITDA(百万ドル) -72.19200
終値(lastsale) 8.59
時価総額(marketcap) 490029976.17
時価総額 時価総額(百万ドル) 484.88320
売上高 売上高(百万ドル) 223.32200
企業価値(EV) 企業価値(EV)(百万ドル) 82.76020
当期純利益 当期純利益(百万ドル) -68.34100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Akebia Therapeutics Inc revenues increased 92% to $94.7M. Net loss decreased 13% to $57.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in R&D decrease of 72% to $1.4M (expense) Interest income increase from $1M to $2.6M (income) Other Non Rec.

 AKBAのテクニカル分析


 AKBAのニュース

   Akebia wins $40M Department of Veterans Affairs contract  2021/06/15 19:06:06 Seeking Alpha
   Cyclerion inks global licensing agreement with Akebia for as much as $585M  2021/06/04 12:36:34 Seeking Alpha
   Cyclerion Reaches Licensing Agreement With Akebia For Oral SGC Stimulator Praliciguat  2021/06/04 12:21:41 Business Insider Markets
(RTTNews) - Cyclerion Therapeutics Inc. (CYCN) said that it has reached a global license agreement with Akebia Therapeutics Inc., a biopharmaceutical company focused on kidney disease, for the development and commercialization of praliciguat, an oral sGC stimulator. As per the terms of the deal, Akebia has obtained an exclusive license to
   Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat  2021/06/04 00:00:00 BioSpace
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that it has entered into an exclusive, global license agreement with Akebia Therapeutics, Inc., a leading biopharmaceutical company focused on kidney disease, for the development and commercialization of praliciguat, an oral sGC stimulator.
   Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021  2021/06/03 00:00:00 BioSpace
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced presentations of data from the global Phase 3 program for vadadustat at the European Renal Association European Dialysis and Transplant Association (ERA-EDTA) Virtual Conference
   Akebia Therapeutics Celebrates World Kidney Day and National Kidney Month  2021/03/11 13:00:00 Yahoo Finance
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, celebrates World Kidney Day and National Kidney Month with the launch of new initiatives to increase awareness of chronic kidney disease (CKD). As reported by the Centers for Disease Control and Prevention, an estimated 37 million adults in the U.S. are affected by CKD, a progressive, irreversible, and often life-altering, illness.
   Akebia Therapeutics (NASDAQ:AKBA) Announces Quarterly Earnings Results  2021/02/26 23:45:15 Transcript Daily
Akebia Therapeutics (NASDAQ:AKBA) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.20), MarketWatch Earnings reports. Akebia Therapeutics had a negative return on equity of 68.51% and a negative net margin of 126.86%. Shares of AKBA stock traded down […]
   Akebia Therapeutics Earnings and Growth Analysis : Stock market Insights & financial analysis  2021/02/25 04:54:00 Stock Market Daily
Akebia Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to Board of Directors  2021/02/18 13:00:00 PR Newswire Media
CAMBRIDGE, Mass., Feb. 18, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of LeAnne M. Zumwalt to its Board of Directors, effective February 16, 2021. Ms….
   Akebia Therapeutics to Report Fourth Quarter and Full-Year 2020 Financial Results and Discuss Recent Business Highlights  2021/02/08 13:00:00 PR Newswire
CAMBRIDGE, Mass., Feb. 8, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the fourth quarter and full-year 2020…
   Akebia Therapeutics to Present at H.C. Wainwright Bioconnect 2021 Conference  2021/01/06 13:00:00 PR Newswire
CAMBRIDGE, Mass., Jan. 6, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will participate in a…
   Akebia Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference  2021/01/04 13:00:00 PR Newswire
CAMBRIDGE, Mass., Jan. 4, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will present…
   AkebiaShares Program: Current Approaches for Managing Hyperphosphatemia and Caring for Patients via Telehealth  2020/12/09 13:00:00 PR Newswire
CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the latest scheduled program of AkebiaShares, a peer-to-peer educational series…
   Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  2020/12/02 21:05:00 PR Newswire
CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 7 newly-hired employees options to purchase an aggregate of 49,000 shares of Akebia's…
   Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference  2020/11/24 13:00:00 PR Newswire
CAMBRIDGE, Mass., Nov. 24, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will participate in the Piper Sandler 32nd Annual Virtual Healthcare…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アケビア・セラピュ―ティクス AKBA Akebia Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)